Sirolimus-eluting coronary stent - Lepu Medical Technology (Beijing)

Drug Profile

Sirolimus-eluting coronary stent - Lepu Medical Technology (Beijing)

Alternative Names: NeoVas BCS - Lepu Medical Technology; NeoVas bioresorbable coronary scaffold - Lepu Medical Technology

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lepu Medical Technology (Beijing)
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Coronary artery disease

Most Recent Events

  • 26 Aug 2017 Efficacy data from a clinical trial in Coronary artery disease presented at the the ESC Congress 2017: Annual Congress of the European Society of Cardiology (ESC-2017)
  • 26 Aug 2017 Lepu Medical Technology (Beijing) completes the clinical trial in Coronary artery disease in China
  • 31 Mar 2017 Phase-II development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top